Objective: We sought to determine the rate of the K65R mutation in patients receiving tenofovir (TDF)-based antiretroviral therapy (ART) with subtype C HIV infection.
Introduction
Tenofovir (TDF) has been part of first-line antiretroviral therapy (ART) for most developed countries since 2001. Because of potency, durability, tolerability, favorable pharmacokinetics and drug interaction profile, TDF quickly emerged as one of the two most commonly prescribed nucleoside reverse transcriptase inhibitors (NRTIs) for antiretroviral-naive individuals [1] . In areas endemic for hepatitis B virus (HBV), TDF has the added benefit of possessing activity against HBV. In April 2010, TDF was introduced as part of first-line ART in the South African national treatment plan, replacing the more toxic antiretroviral, stavudine (d4T) [2] . To date, there are no published reports on the effectiveness of TDF as part of first-line ART in this setting.
The reverse transcriptase mutation K65R results in a four-fold decrease in TDF susceptibility and is selected by TDF, didanosine (ddI), d4T and abacavir [3] . The K65R mutation has been reported in 7-15% of patients failing d4T-containing, ddI-containing or zidovudine (ZDV)containing first-line or second-line ART in South Africa, where subtype C accounts for most HIV-1 infections, compared with 2-5% of patients in parts of the world where infection with subtype B dominates [4] [5] [6] [7] [8] [9] [10] [11] . In-vitro studies provide some evidence for more rapid selection of K65R in subtype C virus [12] [13] [14] . We previously reported the virologic effectiveness and prevalence of drug resistance mutations after initiating first-line ART in South Africa [15] . In this study, we sought to determine the virologic outcomes and rate of K65R emergence among patients with virologic failure after initiating TDF-containing ART as first-line treatment in a clinic in Durban, South Africa.
Methods
A retrospective analysis of HIV-1 drug resistance was conducted at McCord Hospital, which has been treating patients with ART since 2002. All patients initiated on d4T with lamivudine (3TC) or TDF with 3TC and a non-NRTI from 3 August 2010 to 17 March 2011 were included in the analysis. Virologic failure was defined as a viral load more than 1000 copies/ml after 5 months of a first ART regimen. Genotypic resistance testing was performed prospectively as part of a larger research study on all patients with virologic failure using a validated in-house assay. This study was approved by the respective ethics committees at McCord Hospital and by the institutional review boards at Emory University in Atlanta, Georgia, USA and Partners HealthCare Systems in Boston, Massachusetts, USA. All virologic failure patients provided written informed consent for study participation. Important resistance mutations were selected based upon the published mutations on subtype B virus in the Stanford HIV Drug Resistance database. The prevalence of drug-resistant virus in the samples tested was reported with 95% CIs, calculated based upon normal approximation of binomial distribution. Reverse transcriptase and protease resistance mutations were also reported.
Data collected at baseline included age, sex, prior AIDSdefining illnesses, ART treatment history, CD4 cell count and plasma HIV-1 RNA level at time of regimen failure. Analyses were performed using SAS software, version 9.3 (SAS Institute, Cary, North Carolina, USA). All tests of statistical significance were two-sided; associations with P value less than 0.05 were considered to be statistically significant. Continuous variables were compared using the Wilcoxon rank-sum test; categorical variables were compared using the x 2 -test or Fisher's exact test. Univariate and multivariate logistic regression were used to identify variables associated with the presence of K65R. Variables known to be associated with study outcomes, as well as independent variables exhibiting an association with study outcomes in the bivariate analysis at P value of 0.1 or less or odds ratios of at least 1.5 (or 0.6), were advanced into the multivariate analyses.
Results
Of 585 patients initiated on TDF-containing first-line ART, 35 (6.0%) experienced virologic failure. Baseline characteristics of these patients are presented in Table 1 . The median age (range) was 37.3 years (31.2-45.0), 45.7% of the patients were women, 88.6% were on efavirenz and the median duration of TDF and ART was 5.3 (5.0-6.1) and 5.7 (5.2-15.1) months, respectively. The median number of prior AIDS-defining illnesses was 1 (1.0-2.0), with tuberculosis being the most common (74.3%). The median (interquartile range) CD4 cell count at study entry was 105 cells/ml (49-209); the median viral load at study entry (virologic failure) was 47 571 copies/ml (20 708-202 000). Two patients had virus that could not be amplified for resistance genotyping. All isolates were subtype C. Twenty-three (69.7%) of the 33 patients with virologic failure and amplifiable virus had the K65R mutation. Additional mutation frequencies are described in Table 2 .
In contrast, 53 patients initiated a d4T-containing regimen during the same period. Two (3.8%) of these patients had virologic failure and one had the K65R mutation. Additional reverse transcriptase mutations with the K65R included K103N and V106M. Median duration of ART appeared different between the two groups, but no statistical test is reported due to low sample size in the group initiating a d4T-containing regimen. For those commencing d4T, the median duration of ARTwas 13.7 (5.3-22.2) months compared with 5.7 (5.2-15.1) months for TDF. Ten (28.6%) of the 35 TDF patients had prior d4T and had been previously switched to TDF for toxicity (not virologic failure) after a median of 24.8 (15.1-30.1) months on d4T. One of these patients could not be genotyped. Of the remaining nine patients, four (44.4%) had the K65R mutation. Therefore, if these nine patients were excluded from the 33 total patients with amplifiable virus on TDF, then 19 (79.2%) had the K65R mutation.
The following factors were evaluated, using regression analysis, to determine their association with K65R among patients failing a TDF-containing first-line ART: age, sex, regimen, CD4 cell count, viral load, duration of ART and prior AIDS-defining illnesses. No associations were found in univariate regression and, therefore, multivariate models were not constructed.
Discussion
ART has been shown to be effective in the treatment of HIV-1 infection, regardless of the viral subtype. However, specific drug resistance mutations can emerge at different rates and the prevalence of some drug resistance mutations differs depending upon the subtype [7, 16] . An understanding of drug resistance patterns among non-B subtype infections may help to optimize the selection of first-line ART in order to limit the emergence of drug resistance. Resistance pathways, which could compromise the use of second-line antiretroviral drugs through cross-resistance, also vary among different subtypes [17] . This concern may be increased in developing countries where formularies are limited [5] . However, mutations found in combination with K65R in our study either have a minor effect on susceptibility to ZDV or enhance susceptibility to ZDV (e.g. L74V, Y181C, M184V and K65R). Therefore, we expect that ZDV would remain quite active against such viruses.
During the initial ART rollout at McCord Hospital, the K65R mutation in patients failing first-line therapy for at least 6 months was reported in only three patients out of a total of 147 (2.6%) [6] . Although some of these patients had prior suboptimal ART, most were naive and failing on a d4T-based, ddI-based or ZDV-based regimen. In that study, 97.4% of patients had subtype C virus. Of concern, HIV-1 from approximately 20% of patients in areas in which subtype C is endemic carries the K65R mutation, the K70E mutation or both after experiencing virologic failure of a d4T-based or ddI-based ART regimen [5] . K65R was also detected in 7-15% of patients in South Africa, who did not have a response to first-line or second-line regimens with d4T, ddI or ZDV as the nucleoside backbone [2] . Some of the differences in these rates of acquisition of K65R or thymidine analog mutations (TAMs) are doubtless due to treatment regimens and disease stage, as well as limited access to viral load testing in many developing countries.
In this analysis, the findings of relatively fewer M184V mutations and absence of TAMs provide some evidence K65R after TDF-based first-line ART in subtype C Sunpath et al. 1681 Table 1 . Baseline characteristics of patients with virologic failure during first-line antiretroviral therapy with and without tenofovir. of the antagonism that exists between these mutations and K65R. Although the M184V mutation may have emerged early, variants with this mutation would have been overcome by the more fit K65R variants that likely emerged later. Recent data suggest that increased rates of K65R acquisition in subtype C may be due to the nature of the subtype C RNA template. Particularly, reverse transcriptase of subtype C viruses may be especially prone to pausing events at codon 65 due to a polyadenine region that allows for misalignment, misincorporation, strand transfer, insertions, deletions and recombinations, thereby facilitating the acquisition of K65R during reverse 1682 AIDS 2012, Vol 26 No 13 transcription [4] . Ultrasensitive pyrosequencing methods have also shown that K65R can be selectively transmitted as minority species to some populations that have not yet received ART [8] . Transmission of these variants could jeopardize not only first-line ART but also preexposure and postexposure prophylaxis strategies containing TDF [9, 10] .
There are a few limitations of this study that should be noted. First, there may be a selection bias associated with the study population, as is common in retrospective or cross-sectional studies. Patients who were lost to followup, died or changed service providers prior to study entry would not have been included in this analysis. Additionally, the relatively small sample size does not allow for effective comparisons to be made with the concurrent d4T group and could be an explanation for why risk factors for K65R emergence could not be determined. However, it is unlikely that a larger sample size would significantly alter the prevalence of the K65R mutation for patients receiving TDF and comparisons can be made with the historical reports of virologic failure and K65R for patients receiving d4T-containing ART in this same setting.
K65R is uncommon among patients with subtype B who have received either TDF or a combination of TDF and emtricitabine as part of triple antiretroviral drug therapy [2] . The data reported here show very high rates (>65%) of K65R for patients failing TDF-based first-line regimens at McCord Hospital with few additional NRTI mutations. These rates may reflect faster in-vitro selection, longer time on a failing regimen or transmitted drug resistance. Larger numbers of patients and longer follow-up are required to determine whether the emergence of K65R in subtype C is consistent and clinically relevant in this setting. Although risk factors were not identified in this analysis, larger studies may reveal which patients could be at risk for developing K65R. It is an urgent global priority to optimize treatment strategies for HIV infection, regardless of geographic locale. Moreover, this study provides additional evidence that the provision of viral load monitoring and genotypic resistance testing, both before and after ART, needs to be expanded to include all developing countries [18, 19] .
